DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 11-719/S-107

Mayne Pharma (USA) Inc.
Attention: Steve Richardson
Director, Regulatory and Medical Affairs
Mack-Cali Centre II
650 From Road, Second Floor
Paramus, NJ 07652

Dear Mr. Richardson:

Please refer to your supplemental new drug application dated October 29, 2004, received November 1, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Methotrexate Injection.

We acknowledge receipt of your submissions dated November 4 and 22, 2004.

This supplemental new drug application proposes an alternate source of Methotrexate Injection, 25 mg/mL, 2 mL Preserved.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to submitted labeling (package insert, immediate container, and carton labels) submitted October 29, 2004.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 11-719/S-107." Approval of this submission by FDA is not required before the labeling is used.

Given the anticipated drug shortage, similarity in indications between the two forms of labeling (US and Canadian) and the presence of adequate safety precautions, warnings, listing of adverse reactions, and dosing/administration guidelines in the Canadian label, the labeling being used for this product used in Canada may accompany product imported into the US on a temporary basis for a period lasting no longer than 60 days after approval of this NDA supplement.

In light of the above anticipated drug shortage, we have the following three chemistry issues that you must address within 60 days after the approval of this supplemental NDA:

1. Please provide a consolidated API specifications table from the (b)(4) urces you receive i.e., (b)(4) ---------- ------- ---------- Mayne/Faulding.
2. Please provide the extent of testing performed by Mayne on the receipt of API ((b)(4) (b)(4) ---------- .
3. Please provide a consolidated drug product specifications table.

We also acknowledge your e- mail communication dated December 14, 2004 wherein you indicated your intention to withdraw (b)(4) as a supplier of the drug substance when you submit the above information.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Paul Zimmerman, Regulatory Project Manager, at (301) 594-5775.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Richard Pazdur

12/15/04 01:15:42 PM